• Home
  • About
  • Repositories
  • Search
  • Web API
  • Feedback
<< Go Back

Metadata

Name
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Repository
ClinicalTrials.gov
Identifier
clinicaltrials:NCT04449874
Description
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety,
pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or
metastatic solid tumors with a KRAS G12C mutation.
Data or Study Types
clinical trial
Keywords
SHP2, GDC-1971, KRAS G12C, GDC-6036, Erlotinib, Atezolizumab, Bevacizumab, Colorectal Cancer, Non-Small Cell Lung Cancer, Metastatic Solid Tumor, Cetuximab
Source Organization
Unknown
Access Conditions
available
Year
2020
Access Hyperlink
https://clinicaltrials.gov/ct2/show/NCT04449874

Distributions

  • Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT04449874
This project was funded in part by grant U24AI117966 from the NIH National Institute of Allergy and Infectious Diseases as part of the Big Data to Knowledge program. We thank all members of the bioCADDIE community for their valuable input on the overall project.